InvestorsHub Logo
Followers 65
Posts 40018
Boards Moderated 2
Alias Born 07/08/2002

Re: Paulness post# 630

Thursday, 07/01/2021 4:05:15 PM

Thursday, July 01, 2021 4:05:15 PM

Post# of 1386
Looks like a typical buy the rumor, sell the news.


Kintara Therapeutics Shares Drop 7% After Topline Results for Phase 2 Study
BY Dow Jones & Company, Inc.
— 1:16 PM ET 07/01/2021

Kintara Therapeutics Inc. ( KTRA shares were down 7% to $2.11 Thursday after the company reported topline data results from the recurrent arm of its open-label, Phase 2 clinical study of its lead compound, VAL-083.

Volume for the stock was higher than usual, with 19.3 million shares changing hands by 1:05 p.m. ET, compared with a 65-day average volume of 872,000 shares. The stock had been trading as much as 20% higher in premarket trading before turning lower.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent KTRA News